Sam Brusco, Associate Editor01.14.22
Peripheral and coronary artery disease interventional treatment device firm Cardiovascular Systems Inc. (CSI) reported “significant progress” toward commercializing its intravascular lithotripsy (IVL) systems to treat calcific coronary and peripheral artery disease.
Lithotripsy uses non-invasive high-pressure waves to fracture and disrupt pathologic solid masses. Historically, lithotripsy has been used to treat kidney and gall stones. It’s recently found application to treat calcified coronary and peripheral arteries.
CSI has completed feasibility testing for its system’s console and IVL balloon catheters. CSI’s IVL systems aim to improve on limitations of current technology so physicians can cross and treat more difficult atherosclerotic lesions.
Adding a coronary IVL system to CSI’s current portfolio triples its addressable U.S. market to $1.3 billion. The company intends to begin in-human trials for the peripheral IVL system next year.
“The development of an IVL system for the treatment of coronary and peripheral artery disease will uniquely position CSI to provide the right device, for the right lesion, for all physicians,” Scott R. Ward, CSI Chairman, president, and CEO told the press. “We believe the successful execution of this program will greatly expand patient access to care and CSI’s overall market position in complex coronary and peripheral disease.”
CSI’s current commercial portfolio focuses on treating long, diffuse calcified arties below the knee with orbital atherectomy.
Lithotripsy uses non-invasive high-pressure waves to fracture and disrupt pathologic solid masses. Historically, lithotripsy has been used to treat kidney and gall stones. It’s recently found application to treat calcified coronary and peripheral arteries.
CSI has completed feasibility testing for its system’s console and IVL balloon catheters. CSI’s IVL systems aim to improve on limitations of current technology so physicians can cross and treat more difficult atherosclerotic lesions.
Adding a coronary IVL system to CSI’s current portfolio triples its addressable U.S. market to $1.3 billion. The company intends to begin in-human trials for the peripheral IVL system next year.
“The development of an IVL system for the treatment of coronary and peripheral artery disease will uniquely position CSI to provide the right device, for the right lesion, for all physicians,” Scott R. Ward, CSI Chairman, president, and CEO told the press. “We believe the successful execution of this program will greatly expand patient access to care and CSI’s overall market position in complex coronary and peripheral disease.”
CSI’s current commercial portfolio focuses on treating long, diffuse calcified arties below the knee with orbital atherectomy.